188 related articles for article (PubMed ID: 30466750)
21. Germline DDX41 mutant predisposition syndromes: Slow driver states to hematological malignancies.
Chlon TM; Patnaik MM
Am J Hematol; 2023 Nov; 98(11):1673-1676. PubMed ID: 37705260
[No Abstract] [Full Text] [Related]
22. Prevalence and clinical expression of germ line predisposition to myeloid neoplasms in adults with marrow hypocellularity.
Molteni E; Bono E; Gallì A; Elena C; Ferrari J; Fiorelli N; Pozzi S; Ferretti VV; Sarchi M; Rizzo E; Camilotto V; Boveri E; Cazzola M; Malcovati L
Blood; 2023 Aug; 142(7):643-657. PubMed ID: 37216690
[TBL] [Abstract][Full Text] [Related]
23. Identifying patients at risk for hereditary myeloid malignancy syndromes incorporating a novel, self-administered questionnaire to an initial screening platform.
Zahid MF; Moriarty K; Dryden C; Weinberg O; Asif M; Ikpefan R; Anderson JM; Collins RH; Chung SS; Chen W; Patel PA; Madanat YF
Eur J Haematol; 2023 Dec; 111(6):844-850. PubMed ID: 37587783
[TBL] [Abstract][Full Text] [Related]
24. VEXAS syndrome in a patient with DDX41 germline predisposition syndrome.
Kusne Y; Lasho T; Finke C; Patnaik MM; Badar T
Leuk Res; 2024 Jan; 136():107432. PubMed ID: 38159331
[No Abstract] [Full Text] [Related]
25. Prevalence and clinical outcomes of germline variants among patients with myeloid neoplasms.
Kongkiatkamon S; Niparuck P; Rattanathammethee T; Kobbuaklee S; Suksusut A; Wudhikarn K; Ittiwut C; Chetruengchai W; Chuncharunee S; Bunworasate U; Suphapeetiporn K; Rojnuckarin P; Polprasert C
J Clin Pathol; 2024 May; ():. PubMed ID: 38777570
[TBL] [Abstract][Full Text] [Related]
26. Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing.
Ptashkin RN; Ewalt MD; Jayakumaran G; Kiecka I; Bowman AS; Yao J; Casanova J; Lin YD; Petrova-Drus K; Mohanty AS; Bacares R; Benhamida J; Rana S; Razumova A; Vanderbilt C; Balakrishnan Rema A; Rijo I; Son-Garcia J; de Bruijn I; Zhu M; Lachhander S; Wang W; Haque MS; Seshan VE; Wang J; Liu Y; Nafa K; Borsu L; Zhang Y; Aypar U; Suehnholz SP; Chakravarty D; Park JH; Abdel-Wahab O; Mato AR; Xiao W; Roshal M; Yabe M; Batlevi CL; Giralt S; Salles G; Rampal R; Tallman M; Stein EM; Younes A; Levine RL; Perales MA; van den Brink MRM; Dogan A; Ladanyi M; Berger MF; Brannon AR; Benayed R; Zehir A; Arcila ME
Nat Commun; 2023 Oct; 14(1):6895. PubMed ID: 37898613
[TBL] [Abstract][Full Text] [Related]
27. Challenges associated with the identification of germline variants on myeloid malignancy genomic profiling-a Singaporean experience.
Chin HL; Lam JCM; Christopher D; Michelle PL; Junrong BY
Front Oncol; 2023; 13():1182639. PubMed ID: 37860182
[TBL] [Abstract][Full Text] [Related]
28. Case Report of a DDX41 Germline Mutation in a Family with Multiple Relatives Suffering from Leukemia.
Wagner JN; Al-Bazaz M; Forstreuter A; Hammada MI; Hille J; Papingi D; Bokemeyer C; Fiedler W
Biomedicines; 2023 Dec; 12(1):. PubMed ID: 38255170
[TBL] [Abstract][Full Text] [Related]
29. [Suspicion of constitutional abnormality at diagnosis of childhood leukemia: Update of the leukemia committee of the French Society of Childhood Cancers].
Strullu M; Cousin E; de Montgolfier S; Fenwarth L; Gachard N; Arnoux I; Duployez N; Girard S; Guilmatre A; Lafage M; Loosveld M; Petit A; Perrin L; Vial Y; Saultier P
Bull Cancer; 2024 Mar; 111(3):291-309. PubMed ID: 38267311
[TBL] [Abstract][Full Text] [Related]
30. Genomic testing for germline predisposition to hematologic malignancies.
Hwang SM
Blood Res; 2024 Mar; 59(1):12. PubMed ID: 38485837
[TBL] [Abstract][Full Text] [Related]
31. Genetic predispositions to childhood leukemia.
Stieglitz E; Loh ML
Ther Adv Hematol; 2013 Aug; 4(4):270-90. PubMed ID: 23926459
[TBL] [Abstract][Full Text] [Related]
32. MAGPEL: an autoMated pipeline for inferring vAriant-driven Gene PanEls from the full-length biomedical literature.
Saberian N; Shafi A; Peyvandipour A; Draghici S
Sci Rep; 2020 Jul; 10(1):12365. PubMed ID: 32703994
[TBL] [Abstract][Full Text] [Related]
33. Patterns of mutations in TP53 mutated AML.
Welch JS
Best Pract Res Clin Haematol; 2018 Dec; 31(4):379-383. PubMed ID: 30466751
[TBL] [Abstract][Full Text] [Related]
34. Is it time to routinely incorporate MRD into practice?
Ravandi F
Best Pract Res Clin Haematol; 2018 Dec; 31(4):396-400. PubMed ID: 30466755
[TBL] [Abstract][Full Text] [Related]
35. What FLT3 inhibitor holds the greatest promise?
Stone RM
Best Pract Res Clin Haematol; 2018 Dec; 31(4):401-404. PubMed ID: 30466756
[TBL] [Abstract][Full Text] [Related]
36. When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter.
Roloff GW; Griffiths EA
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):35-44. PubMed ID: 30504289
[TBL] [Abstract][Full Text] [Related]
37. Which novel agents for acute myeloid leukemia are likely to change practice?
Pollyea DA
Best Pract Res Clin Haematol; 2018 Dec; 31(4):391-395. PubMed ID: 30466754
[TBL] [Abstract][Full Text] [Related]
38. Overview of non-coding mutations in chronic lymphocytic leukemia.
Spina V; Rossi D
Mol Oncol; 2019 Jan; 13(1):99-106. PubMed ID: 30520556
[TBL] [Abstract][Full Text] [Related]
39. Germline Predisposition to Hematolymphoid Neoplasia.
Weinberg OK; Kuo F; Calvo KR
Am J Clin Pathol; 2019 Aug; 152(3):258-276. PubMed ID: 31309983
[TBL] [Abstract][Full Text] [Related]
40. Somatic and germline genomics in paediatric acute lymphoblastic leukaemia.
Pui CH; Nichols KE; Yang JJ
Nat Rev Clin Oncol; 2019 Apr; 16(4):227-240. PubMed ID: 30546053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
